rFSH vs rFSH+rLH in Dydrogesterone-Based Progestin Protocol: A Prospective Study
Trial Parameters
Brief Summary
This study aims to compare two commonly used hormone treatments for women undergoing IVF. All participants will receive a stimulation protocol that includes dydrogesterone, a medication used to safely control natural hormone surges during treatment. The study will observe women who are treated either with recombinant FSH alone or with a combination of recombinant FSH and recombinant LH-both routinely used options in our clinic. Investigators will prospectively monitor how these treatments affect the growth of ovarian follicles, the number of mature eggs collected, the quality of developing embryos, and early pregnancy outcomes. No additional procedures or medications will be required beyond standard IVF care. The goal is to better understand whether adding recombinant LH provides any measurable benefit in dydrogesterone-based PPOS cycles.
Eligibility Criteria
Inclusion Criteria: * Women aged 20 to 43 years. * BMI \< 30 kg/m². * AMH \> 1 ng/mL. * Undergoing IVF/ICSI treatment with a dydrogesterone-based PPOS protocol. * Women with regular menstrual cycles or clinically acceptable cycle pattern for stimulation. * Ability to provide informed consent and comply with study procedures. * Presence of at least one ovary and eligibility for controlled ovarian stimulation Exclusion Criteria: * Cycle cancellation due to lack of viable embryos. * Prior or planned PGT-A in the same cycle. * Adenomyosis diagnosed by ultrasound or MRI. * Uncorrected uterine anomalies (e.g., bicornuate, unicornuate, didelphys uterus). * Presence of hydrosalpinx. * Use of oral contraceptives or luteal-phase estradiol within 3 months before stimulation. * Refusal or inability to provide informed consent. * Severe systemic disease or contraindication to ovarian stimulation. * Prior bilateral oophorectomy